宏观动态报告 非农数据为何调整?美联储纪要说了什么? -- 美国劳动数据修正与议息会议纪要 一季度 QCEW 公布,非农数据依据其进行大幅下修:美国劳工数据局(BLS)8月21 日 公布了 2024 年一季度的季度就业和薪资普查（QCEW）数据并根据其初次校正了 2024 年 3 月的非农就业数据基准。截至 2024年一季度末,QCEW 显示在失业保险系统覆盖范围 内的未季调就业总人数累计 1.5358 亿个岗位,同比增长 1.35%;相比之下,未季调的非 农就业总人数累计 1.5721 亿个岗位，同比 1.92%。以 2024年 3 月为基准的初次未季调 非农就业总人数下调 81.8 万个岗位,变动约-0.5%,与过往的非农依据 QCEW 的修正最 终值比较,为2009年-0.7%(90.2万)以来的最低值。 ● 非农数据的下修在市场预期范围内,显示劳动市场的新增就业弱于预期但仍有一定韧性, 整体继续弱化;3月的基准调整减少的 81.8 万个岗位将通过折回模型(wadge-back procedure)分摊至过往的11个月当中,即2024年2月至2023年4月当中;从平均值 考虑,每月的非季调非农就业将下调 ...

公司点评报告 · 轻工行业 外销发力实现稳增,内销"一体两翼"均衡发展 核心观点 ● 事件:公司发布 2024 年半年度报告。2024 年上半年，公司实现营收 89.08 亿元，同比+0.34%;归母净利润 8.96 亿元,同比-2.97%;扣非净利润 7.81 亿元,同比-6.76%;基本每股收益 1.09元。24Q2,公司实现营收 45.58亿元, 同比-7.44%;归母净利润 4.76亿元,同比-9.07%;扣非净利润 4.05亿元, 同比-18.45%。 ● 毛利率改善&费用率提升,扣非净利率有所下滑。 2024年上半年,公司综合毛利率为 33.03%,同比+1.52 pct。24Q2,单季毛 利率为 32.98%,同比+1.97 pct,环比-0.1 pct。 2024年上半年,公司期间费用率为 21.27%,同比+2.07 pct。其中,销售/管 理/研发/财务费用率分别为 17.02% / 2.39% / 2.03% /-0.17%,同比分别变动 +0.92 pct / +0.21 pct / +0.65 pct / +0.29 pct。销售费用率提升源于职工薪 酬增长;研发费用率提升源于物料耗 ...

Investment Rating - The report maintains a "Recommended" rating for Tianshan Aluminum [2][3]. Core Views - The company's performance in the first half of 2024 showed a significant increase in net profit, driven by rising aluminum prices, despite a decrease in revenue [2]. - The integrated layout of the aluminum industry chain is becoming increasingly advantageous, enhancing the company's profitability [2]. Summary by Sections Financial Performance - In the first half of 2024, Tianshan Aluminum achieved operating revenue of 13.785 billion yuan, a year-on-year decrease of 6.83%. However, the net profit attributable to shareholders increased by 103.45% to 2.074 billion yuan, and the net profit after deducting non-recurring gains and losses rose by 168.42% to 1.961 billion yuan [2]. - For Q2 2024, the company reported operating revenue of 6.960 billion yuan, a year-on-year decrease of 11.36% but a quarter-on-quarter increase of 1.97%. The net profit attributable to shareholders reached 1.354 billion yuan, up 161.47% year-on-year and 88.06% quarter-on-quarter [2]. Production and Pricing - The company produced 585,400 tons of electrolytic aluminum in the first half of 2024, a year-on-year increase of 1.28%. The average selling price of self-produced electrolytic aluminum rose by 6.7% [2]. - The average domestic price of electrolytic aluminum (including tax) reached 19,798.38 yuan per ton, a year-on-year increase of 7.08% [2]. Industry Positioning - The integrated layout of the aluminum industry chain is highlighted as a competitive advantage, with the company acquiring exclusive purchasing rights for bauxite from a local mining company in Guinea, which is expected to significantly reduce raw material costs [4]. - The report notes that the domestic alumina price (including tax) reached 3,491.77 yuan per ton in the first half of 2024, a year-on-year increase of 20.90% [4]. Future Projections - The forecast for net profit attributable to shareholders for 2024-2026 is 4.114 billion, 4.380 billion, and 5.272 billion yuan, respectively, with corresponding EPS of 0.88, 0.94, and 1.13 yuan, leading to PE ratios of 7.8, 7.3, and 6.1 times [2].

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company achieved significant growth in the first half of 2024, with revenue reaching 1.19 billion yuan, a year-on-year increase of 31.68%, and a net profit attributable to shareholders of 304 million yuan, up 50.53% year-on-year [2][3]. - The company has launched a stock incentive plan targeting a net profit growth rate of no less than 30%, 70%, and 120% for the years 2024 to 2026, respectively, based on the 2023 net profit [9][3]. - The core product, Paigebin, continues to see rapid growth, contributing over 80% of the revenue in Q2 2024, which amounted to 645 million yuan, reflecting a year-on-year growth of 33.09% [2][3]. Financial Performance - In Q2 2024, the company reported a net profit of 176 million yuan, a year-on-year increase of 48.75% and a quarter-on-quarter increase of 36.28% [2]. - The company’s R&D investment in the first half of 2024 was 136 million yuan, with 114 million yuan being expensed and 22 million yuan capitalized [2]. - The projected net profits for 2024, 2025, and 2026 are estimated at 775 million yuan, 1.04 billion yuan, and 1.31 billion yuan, respectively, with growth rates of 39%, 34%, and 27% [9][10]. Research and Development - The company is actively advancing multiple R&D projects, including the completion of Phase III clinical trials for Yipeisheng (growth hormone) and the initiation of Phase III preparations for YPEG-EPO [2]. - A new clinical trial collaboration with Aligos for Paigebin in treating chronic hepatitis B patients has been established [3]. - The company is expanding its R&D capabilities with a new protein drug production and R&D center, which will enhance its overall research strength [2].

Investment Rating - The report maintains a "Recommend" rating for the company, reflecting a positive outlook on its future performance [2] Core Views - The company's Q2 2024 performance was strong, with revenue reaching 7.603 billion yuan, a 33.95% YoY increase, and net profit attributable to shareholders of 2.063 billion yuan, a 92.94% YoY growth [1] - Innovation-driven revenue growth was robust, with innovative drug revenue reaching 6.612 billion yuan in H1 2024, a 33% YoY increase [1] - Internationalization efforts are progressing steadily, with significant licensing deals contributing to revenue growth, including a 1.1 billion USD upfront payment and potential milestone payments up to 5.725 billion USD [2] Financial Performance - H1 2024 revenue was 13.601 billion yuan, a 21.78% YoY increase, with net profit attributable to shareholders of 3.432 billion yuan, a 48.67% YoY growth [1] - R&D investment in H1 2024 was 3.86 billion yuan, with 3.038 billion yuan expensed [1] - The company's gross margin is expected to improve from 84.55% in 2023 to 91.73% by 2026 [5] Product Performance - Key innovative drugs such as Ruiweilu'an, Daerxili, and Henggeliezhin showed rapid growth after entering the national medical insurance catalog [1] - Adebelisumab, though not yet included in the national medical insurance, has been included in local惠民保 programs, contributing to revenue growth [1] - Established innovative drugs like Camrelizumab, Pyrotinib, and Apatinib continued to show sales growth due to new indications and clinical evidence [1] International Expansion - The company licensed its GLP-1 class innovative drugs (HRS-7535, HRS9531, HRS-4729) to Hercules in the US, receiving a 19.9% equity stake in Hercules [2] - A 160 million euro upfront payment from Merck for HRS-1167 and SHR-A1904 projects contributed to revenue growth [2] Financial Projections - Revenue is projected to grow from 22.819 billion yuan in 2023 to 35.498 billion yuan by 2026, with a CAGR of 15.79% [5] - Net profit attributable to shareholders is expected to increase from 4.302 billion yuan in 2023 to 9.391 billion yuan by 2026 [5] - EPS is forecasted to grow from 0.67 yuan in 2023 to 1.47 yuan by 2026 [5] Valuation Metrics - The company's PE ratio is expected to decline from 62.73 in 2023 to 28.74 by 2026 [5] - PB ratio is projected to decrease from 6.67 in 2023 to 4.17 by 2026 [5] - PS ratio is anticipated to drop from 11.83 in 2023 to 7.60 by 2026 [5]

Investment Rating - The report maintains a "Recommended" investment rating for Tonghui Electronics (833509.BJ) [2][5] Core Viewpoints - In the first half of 2024, the company achieved double growth in revenue and profit, with operating income of 86.11 million yuan, a year-on-year increase of 12.78%, and a net profit attributable to shareholders of 18.86 million yuan, up 14.53% year-on-year [1] - The growth in revenue is attributed to the recovery in consumer electronics and significant expansion in the new energy testing sector, with key revenue sources including component parameter testing instruments and safety wire testing instruments [1][2] - The company has maintained a high level of R&D investment, with R&D expenses of 11.84 million yuan in the first half of 2024, a year-on-year increase of 8.97%, and a R&D expense ratio of 13.75% [2] - The share buyback program, announced on June 11, 2024, aims to use self-owned funds to repurchase shares for employee stock ownership plans, reflecting confidence in the company's future development [2][5] Financial Performance Summary - For the first half of 2024, the company reported a gross margin of 55.58% and a net margin of 21.80%, indicating stable profitability levels [1] - The company expects net profits for 2024-2026 to be 45 million, 56 million, and 69 million yuan respectively, with year-on-year growth rates of 16.21%, 24.50%, and 24.06% [5] - The projected operating income for 2024 is 195 million yuan, reflecting a growth rate of 15.16% compared to 2023 [5]

Industry Investment Rating - The report maintains a **"Recommend"** rating for the pharmaceutical and biotechnology industry, driven by the growing momentum of domestic companies expanding overseas [2] Core Views - The dual factors of **overseas market attractiveness** and **domestic market competition pressure** are accelerating the overseas expansion of domestic pharmaceutical companies [2] - The pharmaceutical industry's overseas expansion is transitioning from **APIs and generics** to **innovative drugs**, with **license-out** becoming the dominant model for innovative drug exports [2][25] - Domestic medical device companies are entering a **high-quality development phase** in overseas markets, with product competitiveness gradually reaching global standards [2][43] - The **global pharmaceutical market** is expected to grow at a CAGR of 5.8% from 2021 to 2027, reaching $2 trillion, providing significant opportunities for domestic companies [19] Domestic Pharmaceutical Overseas Expansion - The overseas revenue of A-share pharmaceutical companies grew from **31.175 billion yuan** in 2010 to **246 billion yuan** in 2023, with a CAGR of 17.22% [4] - In 2023, the overseas revenue of A-share pharmaceutical companies accounted for **9.86%** of total revenue, down 2.11 percentage points year-on-year [4] - The overseas gross profit margin of A-share pharmaceutical companies reached **42.59%** in 2023, lower than the domestic gross profit margin of **50.30%** [5] - **Chemical pharmaceuticals**, **medical services**, and **medical devices** are the top three sectors in terms of overseas revenue, contributing **974.86 billion yuan**, **681.63 billion yuan**, and **680.83 billion yuan** respectively in 2023 [7] Pharmaceutical Export Trends - In 2023, China's pharmaceutical exports totaled **$102.06 billion**, a year-on-year decrease of 20.7%, with **Western drugs** accounting for 50% of total exports [10][11] - **APIs** accounted for **$40.91 billion** of exports in 2023, down 20.7% year-on-year, with a **24.7% drop in average export prices** [12] - **Medical device exports** reached **$45.52 billion** in 2023, down 22.8% year-on-year, with traditional medical device exports (excluding pandemic-related products) declining by only **3.1%** [13] - **Traditional Chinese medicine (TCM) exports** totaled **$5.46 billion** in 2023, down 3.3% year-on-year, with **plant extracts** accounting for 59.7% of TCM exports [14] Overseas Market Opportunities - The **global pharmaceutical market** is projected to grow from **$1.4 trillion** in 2021 to **$2 trillion** by 2027, driven by population growth, aging, and improved healthcare systems [19] - The **US pharmaceutical market** is the largest globally, with **innovative drugs** accounting for **79%** of sales in 2021, compared to only **11%** in China [19] - **Overseas pricing advantages** are significant, with US drug prices being **10 times higher** than those in China, providing strong incentives for domestic companies to expand overseas [20][21] Innovative Drug Overseas Expansion - In 2023, domestic companies completed **70 license-out deals**, with a total disclosed transaction value exceeding **$46.5 billion**, a 69% increase from 2022 [25][26] - **Baili Heng's** HER3/EGFR bispecific ADC deal with BMS reached a potential total value of **$8.4 billion**, setting a new record for domestic innovative drug license-out transactions [26] - **Collaborative development** and **independent overseas expansion** models are also gaining traction, with companies like **BeiGene** and **Legend Biotech** achieving significant milestones in the US and European markets [29][31] Medical Device Overseas Expansion - Domestic medical device companies are making breakthroughs in **high-end markets**, with products in **imaging**, **ultrasound**, and **in-vitro diagnostics** reaching global standards [2][43] - In 2023, China's medical device exports totaled **249.1 billion yuan**, with **Asia**, **North America**, and **Europe** being the top three markets, accounting for **34.45%**, **27.92%**, and **26.06%** respectively [49] - **Mindray Medical** and **United Imaging Healthcare** are leading the way in **ultrasound** and **MRI** technologies, with products comparable to those of global leaders like GE and Philips [45][47] API and Generic Drug Overseas Expansion - China is the **largest API producer** globally, with a market share of **30%** in 2022, up from **9.3%** in 2008 [38] - In 2023, China's API exports reached **$40.91 billion**, down 20.7% year-on-year, with **export volume** increasing by **5.4%** despite a **24.7% drop in average prices** [39] - **India** and the **US** are the top two export markets for Chinese APIs, accounting for **12.77%** and **10.39%** of total exports respectively [41]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the coming months [5]. Core Insights - The company reported a revenue of 4.2 billion RMB for Q2 2024, representing a year-on-year increase of 49%. The core OTA business generated 3.2 billion RMB, up 23% year-on-year, aligning with expectations. The net profit attributable to shareholders was 430 million RMB, a 22% increase year-on-year, while adjusted net profit reached 660 million RMB, up 11% year-on-year [2][3]. - Strong demand for travel and international business expansion contributed to the core OTA business's revenue growth. The accommodation booking service generated 1.2 billion RMB, a 13% increase year-on-year, driven by increased accommodation demand and enhanced cross-selling strategies. The transportation booking service achieved 1.7 billion RMB, a 17% increase year-on-year, marking a historical high for quarterly revenue [2][3]. - The user base and purchase frequency continue to grow, with annual paid users reaching 230 million and cumulative service users at 1.86 billion, reflecting year-on-year increases of 4.8% and 29.9%, respectively. The average revenue per user (ARPU) is approximately 64 RMB, a 30% increase compared to 2019 [2][3]. Financial Performance Summary - The company forecasts adjusted net profits of 2.6 billion RMB, 3.5 billion RMB, and 4.2 billion RMB for 2024, 2025, and 2026, respectively. The current stock price corresponds to adjusted P/E ratios of 16X, 12X, and 9X for the same years [4][3]. - Key financial metrics for 2024 include projected revenue of 17.1 billion RMB, a 44% growth rate, and an adjusted net profit of 2.7 billion RMB, reflecting a 21% increase [4][8]. - The gross margin for Q2 2024 was reported at 65%, a decrease of 11 percentage points year-on-year, primarily due to the integration of new offline vacation services and differences in the core OTA business model [2][3].

Investment Rating - The report maintains a "Recommended" rating for the company [1]. Core Views - The company reported a revenue of 7.206 billion yuan for the first half of 2024, a year-on-year increase of 1.14%, and a net profit attributable to shareholders of 548 million yuan, up 18.39% year-on-year [1]. - The gross margin for the first half of 2024 was 17.82%, an increase of 1.88 percentage points year-on-year, while the net profit margin was 7.34%, up 1.24 percentage points year-on-year [1]. - The company is a leader in metal packaging, focusing on its core business while actively expanding its business landscape, with expectations for improved profitability due to industry consolidation [1]. Financial Performance Summary - In Q2 2024, the company achieved a revenue of 3.654 billion yuan, a decrease of 3.13% year-on-year, but the net profit increased by 6.49% to 269 million yuan [1]. - The company’s comprehensive gross margin for the first half of 2024 was 17.82%, with a quarterly gross margin of 17.39% in Q2 [1]. - The company’s operating expenses ratio was 8.34%, an increase of 0.53 percentage points year-on-year, with specific expense ratios for sales, management, R&D, and financial expenses reported [1]. Business Segment Performance - The metal packaging business generated 6.36 billion yuan, a year-on-year increase of 2.66%, while the filling services segment saw a significant increase of 48.49% [1]. - Raw material prices have been declining, with the average market price for tinplate coil at 5,783 yuan/ton, down 5.71% month-on-month [1]. Earnings Forecast - The company is expected to achieve earnings per share of 0.36 yuan, 0.41 yuan, and 0.45 yuan for the years 2024, 2025, and 2026, respectively, with corresponding price-to-earnings ratios of 12X, 11X, and 10X [1][3].

Investment Rating - The report maintains a "Recommend" rating for the company [1] Core Views - The company achieved revenue of RMB 16.629 billion in H1 2024, a YoY increase of 21.67%, but net profit attributable to the parent company decreased by 32.01% YoY to RMB 561 million [1] - The new energy business contributed RMB 3.81 billion in revenue, accounting for 22.91% of total revenue, up 1.35 percentage points YoY [1] - The PCB business, the company's main revenue source, generated RMB 10.85 billion in revenue, a 20.93% YoY increase, but its proportion of total revenue decreased by 0.4 percentage points to 65.25% [1] - The company is actively expanding its PCB products in AI servers, cloud computing, and automotive fields to capitalize on the new technological innovation cycle [1] - The LED business saw a significant improvement in operating efficiency, with losses narrowing despite intense competition [1] - The touch display business has recovered to normal levels, with revenue increasing by 40.73% YoY to RMB 3.122 billion [1] Financial Projections - Revenue is expected to grow from RMB 40.003 billion in 2024 to RMB 58.225 billion in 2026, with a CAGR of 21% [1] - Net profit attributable to the parent company is projected to increase from RMB 1.952 billion in 2024 to RMB 3.352 billion in 2026, with a CAGR of 31% [1] - EPS is forecasted to rise from RMB 1.14 in 2024 to RMB 1.96 in 2026 [1] - The company's PE ratio is expected to decrease from 19x in 2024 to 11x in 2026 [1] Business Segments - The company's product lines cover electronic circuits, optoelectronic displays, and precision manufacturing, focusing on consumer electronics and new energy sectors [1] - The PCB business has a strong customer base, including global leaders in consumer electronics and new energy vehicles [1] - The company is leveraging AI applications to drive innovation and expand its customer base in emerging technology fields [1] Financial Ratios - The company's ROE is expected to improve from 12.58% in 2024 to 13.33% in 2026 [5] - The debt-to-asset ratio is projected to decrease from 58.27% in 2024 to 56.24% in 2026 [5] - The net debt ratio is expected to decline significantly, from 33.72% in 2024 to -0.11% in 2026 [5]